Anebulo reports Q2 FY2022 net loss $1.1M; starts Phase 2 trial for ANEB-001; appoints new CEO

Anebulo Pharmaceuticals, Inc.

Net loss $1.1M ($0.05/sh) vs $0.3M ($0.03/sh) in Q2 FY2021; operating expenses $1.1M.
Cash and cash equivalents $18.0M as of Dec 31, 2021; cash burn $1.2M in Q2.
Initiated Phase 2 proof-of-concept study for ANEB-001 for acute cannabinoid intoxication; topline results expected H1 2022.
Simon Allen appointed CEO effective Feb 1, 2022; previously CBO at Ambrx.
FDA pre-IND meeting provided guidance; U.S. patent issued for ANEB-001 (expires 2040).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.